HU

Hutchmed (China) Limited

Overview

Corporate Details

ISIN(s):
KYG4672N1198 (+1 more)
LEI:
2138006X34YDQ6OBYE79
Country:
Hong Kong
Address:
LEVEL 18, THE METROPOLIS TOWER, KOWLOON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 08:00
Board/Management Information
Directorate Change
English 17.9 KB
2025-08-20 08:00
Regulatory News Service
HUTCHMED Completes Enrollment of Phase III Trial
English 29.1 KB
2025-08-07 13:00
Earnings Release
2025 Interim Results
English 141.5 KB
2025-07-03 10:30
Report Publication Announcement
HUTCHMED to Announce 2025 Half-Year Results
English 12.1 KB
2025-06-30 10:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 12.4 KB
2025-06-30 10:30
Remuneration Information
Blocklisting Six Monthly Return
English 25.1 KB
2025-06-30 10:30
Regulatory News Service
China Approval based on Phase III SACHI Trial
English 29.8 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.